US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

24.50

-0.6200-2.47%

Post-market: 25.521.02+4.16%19:30 EDT

Volume:57.51K

Turnover:1.41M

Market Cap:56.84M

PE:- -

High:25.32

Open:25.24

Low:24.14

Close:25.12

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:1.27

T/O Rate:2.48%

Dividend:1.70

Dividend Rate:6.95%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval

THOMSON REUTERS

NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting

THOMSON REUTERS

FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

THOMSON REUTERS

These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Wingara Ag sets AGM to approve capital raising tools and board re-elections

Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer

Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses

Relmada Therapeutics Q2 EPS USD -0.11

Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

The Race to Come up with the Next Big Sleep Drug

Compass Pathways is Maintained at Overweight by Morgan Stanley

Compass Pathways price target raised to $22 from $17 at B. Riley

RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating

MT Newswires Live

Praxis Precision Q2 Net Loss Widens on Higher Expenses

Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs

GH Research Plc Q2 EPS USD -0.23

THOMSON REUTERS

GH Research Says H1 Loss Widens as R&D Spending Rises on GH001 Clinical, Technical Development Work

Scholar Rock Q2 Net Loss Narrows

GH Research Publishes Corporate Presentation on Ultra-Rapid, Durable Remission Data for TRD Treatment GH001

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/PSIL/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":24.5,"timestamp":1789502400000,"preClose":25.12,"halted":0,"volume":57505,"hourTrading":{"tag":"盘后","latestPrice":25.52,"preClose":24.5,"latestTime":"19:30 EDT","volume":168,"amount":4296.44,"timestamp":1789515005327,"change":1.02,"changeRate":0.041633,"amplitude":0.041633},"delay":0,"changeRate":-0.024681528662420422,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Not Yet Opened","change":-0.62,"latestTime":"09-15 16:00:00 EDT","open":25.24,"high":25.3215,"low":24.14,"amount":1405286.14317,"amplitude":0.047034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":25.12,"sharesOutstanding":1184976,"nav":25.051,"aum":58118072.21,"dividendRate":0.069514,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":25.52,"preClose":24.5,"latestTime":"19:30 EDT","volume":168,"amount":4296.44,"timestamp":1789515005327,"change":1.02,"changeRate":0.041633,"amplitude":0.041633},"volumeRatio":1.273508,"impliedVol":0.4953,"impliedVolPercentile":0.8446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.273508,"shares":2319976,"dividePrice":1.7031,"high":25.3215,"amplitude":0.047034,"preClose":25.12,"low":24.14,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":24.5,"eps":0,"divideRate":0.069514,"volume":57505,"delay":0,"ttmEps":0,"open":25.24,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.96,"twentyDayClose":25.83,"sixtyDayClose":20.0904},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657617087","title":"NRX Pharmaceuticals - no New Clinical or Safety Data Required for Ketamine Anda Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657617087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657617087?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657170556","title":"NRX Pharmaceuticals - FDA to Review Certification in Shortest Possible Cycle After Aug 6, 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2657170556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657170556?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161707","title":"FDA Completes First-Cycle Review of Preservative-Free Ketamine Anda with no Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657161707?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:00","pubTimestamp":1786100400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nTUA1BNQYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657699541","title":"These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657699541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657699541?lang=en_us&edition=fundamental","pubTime":"2026-08-07 13:15","pubTimestamp":1786079700,"startTime":"0","endTime":"0","summary":"Biotech stocks have recaptured investors' attention this year amid a wave of drug innovation, which is spurring merger-and-acquisition activity in the biopharma industry and a fresh round of initial p","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXH","LU2596442595.SGD","FHLC","PPH","LU1974910355.USD","BK4578","IYH","PBLS","IE000M9KFDE8.USD","BMED","NVS","PSIL","LU1061106388.HKD","LU1037948541.HKD","MRK","RXL","XBI","PAWZ","LU2125154778.USD","LU1929549753.HKD","XLV","LU0456855351.SGD","BMY","IE00BJJMRZ35.SGD","LU2461242641.AUD","LU0980610538.SGD","LU1023059063.AUD","TRUH","LU1430594728.SGD","HRTS","IHE","LU0061475181.USD","NVIB","LU0320765489.SGD","SG9999001440.SGD","LU0965508806.USD","SG9999014575.USD","LU1934455194.USD","IE00B1BXHZ80.USD","IXJ","GDOC","LU0122379950.USD","LU1941712348.USD","LU2491050154.USD","BBC","VHT","MEDX","LU0306807586.USD","JDOC","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657529664","title":"Wingara Ag sets AGM to approve capital raising tools and board re-elections","url":"https://stock-news.laohu8.com/highlight/detail?id=2657529664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657529664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:29","pubTimestamp":1786058949,"startTime":"0","endTime":"0","summary":"Wingara Ag Ltd. ( ($AU:WNR) ) has issued an update. Wingara Ag Ltd has called its Annual General Meeting for 7 September 2026 in Melbourne, where s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/wingara-ag-sets-agm-to-approve-capital-raising-tools-and-board-re-elections?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/wingara-ag-sets-agm-to-approve-capital-raising-tools-and-board-re-elections?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","AGM","BK4229","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666177","title":"Relmada Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666177","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666177?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:49","pubTimestamp":1786052975,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryRelmada Therapeutics IncRLMD.OQreported a quarterly adjusted loss of 11 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433IS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","RLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657931666","title":"Relmada Publishes Investor Presentation Highlighting NDV-01 Program for Non-Muscle Invasive Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657931666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657931666?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:41","pubTimestamp":1786052519,"startTime":"0","endTime":"0","summary":"Relmada publishes investor presentation highlighting NDV-01 program for non-muscle invasive bladder cancerRelmada outlined NDV-01 as its lead program, a sustained-release intravesical gemcitabine/doce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1WTVbn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","PSIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2324357040.USD","LU2065171311.SGD","LU0320765992.SGD","SBIO","IBRN","LU0154245673.USD","IE00BJT1NW94.SGD","LU2065169927.USD","IE00BJJMRZ35.SGD","IMRX","IE00B2B36J28.USD","BK4563","BK4539","BK4139","IE0002141913.USD","LU2065170008.USD","NBIX","PSIL","LU0889565916.HKD","LU0823416689.USD","IE0009355771.USD","LU0109394709.USD","LU2065171402.SGD","PRAX","XENE","IE00BFTCPJ56.SGD","GHRS","LU0154245756.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657579136","title":"Relmada Therapeutics Q2 EPS USD -0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2657579136","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657579136?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:06","pubTimestamp":1786046764,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Q2 EPS USD -0.11Aug 06 (Reuters) - Relmada Therapeutics Q2 net income USD -12.9 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX88ZKJR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","RLMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657184","title":"Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657184?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:05","pubTimestamp":1786046700,"startTime":"0","endTime":"0","summary":"-- Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP. manufacturing of clinical trial material underway. Initiation of the. Phase 3 RESCUE registrational program upon IND clearance.-- Sepranolone IND filing expected by year-end 2026 and initiation of Phase. 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance.-- Strengthened the leadership team with appointment of Bipin Dalmia as. -- Added to the Russell 2000 and Russell 3000 Indexes effective June. -- Cash balance of $217.7 million as of June 30, 2026, expected to fund. operations through 2029, including completion of the NDV-01 Phase 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","BK4588","LU0149725797.USD","LU2092937221.SGD","BK4007","IE00BHPRN162.USD","IE00BFXG1179.USD","BK4121","LU0971096721.USD","A","IND","LU2237443622.USD","LU2229751404.USD","LU2237443549.SGD","LU2746668461.USD","LU2237443978.SGD","IE00BKVL7J92.USD","LU1543694498.USD","IE00BN0W2W23.USD","R","PWS","CMC","RLMD","IE00BN0W2T93.GBP","BK4139","IE00B1BXHZ80.USD","LU2237443895.HKD","LU0347712357.USD","BK4006","LU1721428933.USD","PSIL","LU1721429402.USD","IE00BZ1G4Q59.USD","BK4567","EES","BK4505","LENZ","IE00BN0W2V16.EUR","LU2041044095.USD","ALLO","LU2089279066.USD","LU1721429741.USD","LU2237443465.HKD","LU2413666699.HKD","BK4232","LU2413666426.HKD","LU0882574139.USD","BK4585","LU2746668974.SGD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651052","title":"The Race to Come up with the Next Big Sleep Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651052?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:30","pubTimestamp":1786041000,"startTime":"0","endTime":"0","summary":"Narcolepsy isn't easy to treat. Existing drugs manage patients' symptoms -- notably excessive daytime sleepiness and difficulty sleeping at night -- rather than the cause. Yet a new type of drug is em","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0094547139.USD","LU1548497426.USD","GB00BDT5M118.USD","LU2602419157.SGD","WDNA","LU2089283258.USD","IE00B4JS1V06.HKD","LU0238689110.USD","LU1035775433.USD","LU1868837300.USD","LU0109391861.USD","IE00BFSS8Q28.SGD","IE00B1BXHZ80.USD","LU2324357040.USD","LU2491050071.SGD","LU0683600562.USD","SGXZ51526630.SGD","SG9999014898.SGD","LU0058720904.USD","LU0256863902.USD","LU2112291526.USD","LU2756315664.SGD","LU2211815571.USD","BK4516","LU0640476718.USD","IHE","ELIL","LU2361045086.USD","SG9999015945.SGD","IE00B1XK9C88.USD","LU2750360641.GBP","TMED","LU1623119135.USD","LU2417539215.USD","SG9999015978.USD","IBRN","LU2237443978.SGD","LU0096364046.USD","LU1023059063.AUD","ALKS","IYH","LU1280957306.USD","LU0266013472.USD","SGXZ99366536.SGD","LU2237443895.HKD","LU2237438978.USD","BK4139","IE00BK4W5M84.HKD","IE00B2B36J28.USD","LU0882574139.USD","LU1323610961.USD","LU0354030438.USD","LU2456880835.USD","LU2264538146.SGD","LU2265009873.SGD","LU0689472784.USD","LU2552382215.SGD","LU2168564065.EUR","ILDR","BK4534","LU0109394709.USD","IE00BFSS7M15.SGD","LU0323591593.USD","LU0820562030.AUD","LU0823434583.USD","LU2168564495.EUR","LU1366192091.USD","LLY","LU2237443465.HKD","THNR","LU1291159041.SGD","PPH","LU0133085943.USD","LU0672654240.SGD","LU0079474960.USD","IE0004445015.USD","LU2063271972.USD","LU1069344957.HKD","LU1720051017.SGD","LU0353189763.USD","LU0097036916.USD","AGNG","LU1720051108.HKD","GDOC","SG9999018857.SGD","LU0820561818.USD","LU1232071149.USD","LU1551013342.USD","LU1917777945.USD","LU2087625088.SGD","LU2471134952.CNY","LU0345770993.USD","LU0106261372.USD","VHT","LU1989771016.USD","LU2896262040.SGD","LU1629891620.HKD","LU0964807845.USD","LU1814569148.SGD","LU0158827948.USD","LU2491050154.USD","PJP","RXL","LU2237443549.SGD","LU0432979614.USD","IXJ","TAK","LLYX","LU0225283273.USD","LU0210536198.USD","LU0471298777.SGD","LU1145028129.USD","LU2462591350.SGD","IE0001KFT4U8.USD","MEDI","LU0456855351.SGD","SGXZ81514606.USD","LU2168564149.EUR","LLYZ","LU0006306889.USD","LU2028103732.USD","LU0385154629.USD","LU2552382132.HKD","LU2111349929.HKD","SG9999001176.USD","LU1267930730.SGD","BK4007","LU2361044949.HKD","LU0823434740.USD","LU1057294990.SGD","LU1093756168.USD","LU0354030511.USD","LU2462157665.USD","IE00BKPKM429.USD","LU0471298694.HKD","FBT","PSCH","IE00B7KXQ091.USD","IE00BK4W5L77.USD","LU0466842654.USD","LU1064131342.USD","LU0320765059.SGD","IE00BFTCPJ56.SGD","LU2271345857.HKD","PSIL","LU0820561909.HKD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU0882574055.USD","BK4585","LU1974910355.USD","LU1983299246.USD","LU1093756325.SGD","BK4599","LU1988902786.USD","IE00BN29S564.USD","LU0353189680.USD","IE00BJJMRX11.SGD","JDOC","LU0943347566.SGD","SGXZ31699556.SGD","LU0234572021.USD","MHIP","SG9999001176.SGD","BK4533","HRTS","LU0316494557.USD","BK4588","CURE","IE00B775H168.HKD","IE00BJJMRZ35.SGD","LU1868837136.USD","IE00BWXC8680.SGD","LU2471134523.USD","LU1868836591.USD","IE00BJLML261.HKD","FHLC","IE0002141913.USD","LU1712237335.SGD","LU2023250330.USD","LU0122379950.USD","LU2168564222.USD","CANC","IE00BJJMRY28.SGD","SG9999014880.SGD","LU2089984988.USD","SG9999015986.USD","LU2756315318.SGD","OZEM","LU2237443622.USD","LU2471134879.HKD","LU0417517546.SGD","LU0889565916.HKD","LU2108987350.USD","TRUH","LU2023250504.SGD","LU1061106388.HKD","LU1868836914.USD","LU2236285917.USD","LU2237443382.USD","LU2360106947.USD","BK4581","LU0345770308.USD","IE0005OL40V9.USD","LU0061475181.USD","LU2461242641.AUD","LU0174119429.USD","SG9999017495.SGD","LU2106854487.HKD","SG9999014914.USD","LU2023251221.USD","LU2168563687.JPY","LU1127390331.HKD","LU2491049909.HKD","LU2750360997.AUD","LU2357305700.SGD","SG9999014906.USD","SG9999018865.SGD","SGXZ57979304.SGD","LU0203201768.USD","LU1979441026.SGD","LU0158827781.USD","LU2471134796.USD","LU1804176565.USD","IE00B4R5TH58.HKD","IE00BKDWB100.SGD","LU2468319806.SGD","LU0198837287.USD","LU0203202063.USD","FTXH","LU2089284900.SGD","SG9999015952.SGD","LLII","SG9999013999.USD","LU0786609619.USD","LU2361044865.SGD","LU1551013425.SGD","LU0787776722.HKD","LU0823416689.USD","IE0004445239.USD","LU2746668461.USD","XLV","LU1868836757.USD","LU0256863811.USD","LU0708995401.HKD","LU2552382058.USD","LU2213496289.HKD","ELIS","LU2746668974.SGD","MEDX","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651829","title":"Compass Pathways is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651829","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651829?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:55","pubTimestamp":1786038900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637864","title":"Compass Pathways price target raised to $22 from $17 at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637864?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:38","pubTimestamp":1786023496,"startTime":"0","endTime":"0","summary":"B. Riley analyst Madison El-Saadi raised the firm’s price target on Compass Pathways (CMPS) to $22 from $17 and keeps a Buy rating on the shares po...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-raised-to-22-from-17-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-raised-to-22-from-17-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631659","title":"RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631659","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631659?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:32","pubTimestamp":1786019564,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $23.35, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657395516","title":"Praxis Precision Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657395516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657395516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018371,"startTime":"0","endTime":"0","summary":"Praxis Precision Q2 net loss widens on higher expensesOverviewUS CNS drug developer's Q2 net loss widened yr/yr on higher operating expensesCompany ended Q2 with $1.4 bln in cash and investments, fund","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HRMY","PSIL","IE0002141913.USD","IE00B2B36J28.USD","BK4139","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","GHRS","IE0009355771.USD","LU0889565916.HKD","IBRN","VNDA","LU0320765992.SGD","BK4539","BK4007","LU0109394709.USD","IE00BFTCPJ56.SGD","PRAX","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663689","title":"Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663689","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663689?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:58","pubTimestamp":1786017486,"startTime":"0","endTime":"0","summary":"Ireland's GH Research Q2 net loss widens on higher R&D costsOverviewIreland biopharmaceutical firm's Q2 net loss widened yr/yr, with higher R&D and G&A expensesCompany's cash and marketable securities","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","GHRS","LU0320765992.SGD","LU0109394709.USD","IE00BN0W2V16.EUR","BK4533","IE00BN0W2W23.USD","BK4139","LU0823416689.USD","BK4539","LU0154245673.USD","BK4007","CMPS","IE00BN0W2T93.GBP","JAZZ","LU0154245756.USD","PSIL","CNTX","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657359246","title":"GH Research Plc Q2 EPS USD -0.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2657359246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657359246?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:42","pubTimestamp":1786016572,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXPBJD44:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4539","BK4007","GHRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657926633","title":"GH Research Says H1 Loss Widens as R&D Spending Rises on GH001 Clinical, Technical Development Work","url":"https://stock-news.laohu8.com/highlight/detail?id=2657926633","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657926633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:26","pubTimestamp":1786015613,"startTime":"0","endTime":"0","summary":"GH Research says H1 loss widens as R&D spending rises on GH001 clinical, technical development workGH Research posted a net loss of USD 34.11 million for the six months ended June 30, 2026, driven by ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3lWYPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PSIL","GHRS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657692633","title":"Scholar Rock Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657692633","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657692633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015339,"startTime":"0","endTime":"0","summary":"Scholar Rock Q2 net loss narrowsOverviewUS biopharmaceutical firm's Q2 net loss narrowed slightly yr/yr with no revenue recordedOperating expenses for Q2 fell, driven by reduced research and developme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IBRN","THNR","CMPS","BK4584","MNKD","BK4139","SRRK","BDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633319","title":"GH Research Publishes Corporate Presentation on Ultra-Rapid, Durable Remission Data for TRD Treatment GH001","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633319","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633319?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:19","pubTimestamp":1786015157,"startTime":"0","endTime":"0","summary":"GH Research publishes corporate presentation on ultra-rapid, durable remission data for TRD treatment GH001GH Research highlighted Phase 2b data for GH001, an inhaled mebufotenin candidate for treatme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL1w2P6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GHRS","PSIL","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}